Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Immunology, Immunotherapy is Scopus-indexed (Q1, CiteScore 9.5), WoS SCIE, DOAJ. Published by Springer Science and Business Media Deutschland GmbH.
Checked against the index lists dated .
ISSN 0340-7004Verify ISSN ↗1432-0851Verify ISSN ↗
Publisher: Springer Science and Business Media Deutschland GmbH
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 61 / 428 | 85th | Q1 |
| Immunology and Allergy | 39 / 234 | 83rd | Q1 |
| Immunology | 46 / 243 | 81st | Q1 |
| Cancer Research | 56 / 233 | 76th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1976–present, best quartile Q1, CiteScore 9.5.
Cancer Immunology, Immunotherapy is Q1 in Oncology (rank 61 of 428), Q1 in Immunology and Allergy (rank 39 of 234) and Q1 in Immunology (rank 46 of 243), by CiteScore 2025. It is ranked in 4 subject areas in all.
Cancer Immunology, Immunotherapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.5, which places it in quartile Q1 at the 85th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.805, quartile Q1, with an H-index of 148.
The publisher lists an article processing charge of about US$4,590 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Immunology, Immunotherapy is published by Springer Science and Business Media Deutschland GmbH. Its print ISSN is 0340-7004 and its online ISSN is 1432-0851.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Immunology, Immunotherapy has an h-index of 166 and a 2-year mean of 5.46 citations per paper (OpenAlex). Its Scopus CiteScore is 9.5, quartile Q1. On 2-year citations it ranks #49 of 424 Scopus journals in Oncology.
Cancer Immunology, Immunotherapy published 374 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (41.9%), Japan (13.1%) and United States (6.7%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 6 retracted papers are recorded (0.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.